Seaport Therapeutics
SPTX · Nasdaq · United States
Share price · SPTX
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento
Unusual price moves
Days when SPTX's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked
- 28 Sep 2026-8.7%
Nothing announced by SPTX that day or the session before.
- 26 Aug 2026+12.1%
Nothing announced by SPTX that day or the session before.
- 8 Jul 2026+16.6%
Nothing announced by SPTX that day or the session before.
Share of unusual movement by asset
For each asset, the share of SPTX's own-move activity since 4 May 2026 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.
| Asset | Event days | Share of unusual movement |
|---|---|---|
GlyphAllo (allopregnanolone prodrug) (SPT-300)events and moves
| 1 | shown from 8 days |
| Assets with fewer than 8 event days, together | — | 5% |
| Other company news (earnings, financing, releases naming no asset) | — | 18% |
| Sessions with no dated event | — | 77% |
Assets
(1 total)
| Target & Modality | |||
|---|---|---|---|
GlyphAllo (allopregnanolone prodrug)(SPT-300) | Phase 2 | GABA-A receptorSmall molecule | Major Depressive Disorder |
Upcoming events
(2 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2027 (2)
March 2027 (1)
What to watch
May 2027 (1)
What to watch
Regulatory and conference events
(1)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent
Financial reports
Quarterly & interim (6)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q3 | — | $24M | $62M+ $229M short-term inv. | $26M-$23M operating cash flow | report ↗ |
View 5 more
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q2 | — | $25M | $64M+ $209M short-term inv. | $63M-$26M operating cash flow | report ↗ |
| 2026-Q1 | — | $21M | $53M+ $130M short-term inv. | $25M-$20M operating cash flow | report ↗ |
| 2025-Q3 | — | $20M | — | $23M-$16M operating cash flow | report ↗ |
| 2025-Q2 | — | $13M | — | $15M-$15M operating cash flow | report ↗ |
| 2025-Q1 | — | $11M | — | $13M-$20M operating cash flow | report ↗ |
Annual history (1 year)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | — | — | $46M+ $170M short-term inv. | — | report ↗ |
Seaport Therapeutics reported cash and equivalents of $46.04M for fiscal year 2025.
Figures only: this period's report disclosed no narrative text
Insider transactions
Open-market activity, trailing 12 months: 3 purchases ($20.1M), 0 sales ($0). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.
| Source | ||||||
|---|---|---|---|---|---|---|
| 2026-11-10 | Zohar Daphne · director, Chief Executive Officer | Gift | 100,000 | — | — | Form 4 |
| 2026-11-03 | Torres Denice · director | Open-market purchase | 5,000 | $19.86 | $99K | Form 4 |
| 2026-06-22 | HOMBACH ROBERT J. · director | Open-market purchase | 13,000 | $18.14 | $236K | Form 4 |
| 2026-05-04 | PureTech Health plc; PureTech LYT, Inc. · 10% owner; 10% owner | Conversion | 12,736,014 | — | — | Form 4 |
| 2026-05-04 | PureTech Health plc; PureTech LYT, Inc. · 10% owner; 10% owner | Conversion | 2,681,265 | — | — | Form 4 |
| 2026-05-04 | PureTech Health plc; PureTech LYT, Inc. · 10% owner; 10% owner | Conversion | 965,255 | — | — | Form 4 |
| 2026-05-04 | PureTech Health plc; PureTech LYT, Inc. · 10% owner; 10% owner | Conversion (derivative) | 40,000,000 | — | — | Form 4 |
| 2026-05-04 | PureTech Health plc; PureTech LYT, Inc. · 10% owner; 10% owner | Conversion (derivative) | 8,421,052 | — | — | Form 4 |